Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1997036869) N-(2 OXOACETYL OR SULPHONYL)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/1997/036869 International Application No.: PCT/US1997/004916
Publication Date: 09.10.1997 International Filing Date: 24.03.1997
Chapter 2 Demand Filed: 29.10.1997
IPC:
C07D 211/60 (2006.01) ,C07D 401/12 (2006.01) ,C07D 405/06 (2006.01) ,C07D 405/12 (2006.01) ,C07D 405/14 (2006.01) ,C07D 409/12 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
211
Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
04
with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
06
having no double bonds between ring members or between ring members and non-ring members
36
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
60
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02
containing two hetero rings
06
linked by a carbon chain containing only aliphatic carbon atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
409
Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
Applicants:
VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street Cambridge, MA 02139-4242, US
Inventors:
ARMISTEAD, David, M.; US
SAUNDERS, Jeffrey, O.; US
Agent:
HALEY, James, F., Jr. ; Fish & Neave 1251 Avenue of the Americas New York, NY 10020-1104, US
VOSSIUS & PARTNER GbR; Siebertstrasse 4 D-81675 München, DE
Priority Data:
08/626,25929.03.1996US
Title (EN) N-(2 OXOACETYL OR SULPHONYL)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY
(FR) DERIVES D'ACIDE N-(2 OXOACETYLE OU SULFONYLE)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIQUE PRESENTANT UNE MEILLEURE ACTION DANS LES CAS DE RESISTANCE MULTIPLE AUX ANTI-CANCEREUX
Abstract:
(EN) The present invention relates to compounds of formula (I) and (II) that can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of the development of multi-drug resistance, and for use in multi-drug resistant cancer therapy.
(FR) Cette invention se rapporte à des composés représentés par les formules (I) et (II), qui peuvent entretenir, augmenter ou rétablir la sensibilité des cellules à des agents thérapeutiques ou prophylactiques. Cette invention se rapporte également à des compositions pharmaceutiques contenant ces composés. Ces composés et ces compositions pharmaceutiques sont particulièrement indiqués dans le traitement de cellules présentant une résistance multiple aux anti-cancéreux, dans la prévention du développement d'une résistance multiple aux anti-cancéreux, et pour être utilisés dans la thérapie contre le cancer en cas de résistance multiple aux anti-cancéreux.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU
African Regional Intellectual Property Organization (ARIPO) (GH, KE, LS, MW, SD, SZ, UG)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)